Stenotrophomonas maltophilia: changing spectrum of a serious bacterial pathogen in patients with cancer

Area of Science:

• Infectious Diseases
• Oncology
• Microbiology

Background:

• Stenotrophomonas maltophilia infections and colonization have markedly increased in cancer patients over the last two decades.
• Risk factors include prolonged neutropenia, broad-spectrum antibiotic exposure, and mechanical ventilation, with carbapenem use linked to S. maltophilia selection due to intrinsic resistance.
• Emerging infections are noted in patients lacking traditional risk factors.

Purpose of the Study:

• To review the increasing incidence, clinical spectrum, and therapeutic challenges of Stenotrophomonas maltophilia infections in cancer patients.
• To highlight the growing resistance patterns and explore potential alternative treatment strategies.

Main Methods:

• Literature review focusing on recent trends in S. maltophilia epidemiology and clinical management in oncology.
• Analysis of antimicrobial resistance patterns, particularly to trimethoprim-sulfamethoxazole and other agents.
• Discussion of current and potential future therapeutic interventions.

Main Results:

• S. maltophilia infections present with a wide spectrum, including bacteremia, pneumonia, and various localized infections.
• Intrinsic resistance to carbapenems is a key feature, and resistance to trimethoprim-sulfamethoxazole is increasing.
• Susceptibility to alternative antimicrobial agents is often unpredictable, complicating treatment decisions.

Conclusions:

• Effective management of S. maltophilia in cancer patients is challenging due to rising resistance and unpredictable drug susceptibility.
• Combination therapies, alternative drug administration routes (e.g., aerosolized aminoglycosides), and novel therapeutic targets are crucial for addressing multidrug-resistant strains.
• Further research into resistance mechanisms and novel agents is needed to improve outcomes for these difficult-to-treat infections.